Kymera drug positioned to rival Sanofi and Regeneron’s Dupixent succeeds in early-stage eczema trial
Now, the company will aim to show the drug helps patients with eczema and asthma in larger, placebo-controlled trial.
So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is included among the 14 Best US Stocks to Buy for Long Term. On December 4, ...
After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this ...
Investor's Business Daily on MSN
Kymera rockets, pulling Nurix higher. Does it have the next Dupixent?
Kymera Therapeutics could have the next Dupixent, analysts said Monday, as shares skyrocketed on promising test results in ...
We recently published 13 Best ADR Stocks to Invest In. Sanofi (NASDAQ:SNY) is one of the best ADR stocks. Sanofi (NASDAQ:SNY) ...
By the way, GSK, realizing its potential in the MSI-H/dMMR market, is actively developing it for the treatment of colon ...
Sanofi (NASDAQ:SNY) is among the cheap healthcare stocks to buy heading into 2026. As of December 7, Sanofi (NASDAQ:SNY) has ...
The European Medicines Agency has recommended the approval of GSK's add-on drug to treat asthma and a chronic inflammatory ...
ADRs, or American Depository Receipts, are the US-listed securities of foreign firms that allow investors in America to buy ...
The biotechnology sector is characterized by significant price swings, and Regeneron Pharmaceuticals is currently navigating one such period. Although the co ...
Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback